Filing Signals

Source: SEC EDGAR Compiled 2026-09-14 08:28 UTC All 21 checks passing

← All events

Silence Therapeutics plc

CIK 1479615 SLN·Pharmaceutical Preparations · All EDGAR filings ↗

Progression

  1. Going concern 10-K
  2. SEC comment letter UPLOAD +152d
Refine
Form
An amendment is grouped with the report it amends; every 12b-25 notice is one group

SEC comment letter Filing comparison

SEC staff questioned Silence Therapeutics plc's accounting for MD&A

Letter dated 2025-12-18; published on EDGAR 2026-08-04 — the SEC releases comment letters only after the review closes.

Evidence
Direction
staff to company
Letter dated
2025-12-18
Published on edgar
2026-08-04
Reviewing
Silence Therapeutics plc Form 10-K fo the fiscal year ended December 31, 2024 File No. 001-39487 Dear Rhonda Hellums: We have limited our review of your filing
Source
SEC staff comment letter (UPLOAD)
Topics
MD&A
Why
SEC staff reviewed the company's periodic report and raised written comments on its accounting, or the company replied to them. Letters are published on EDGAR only after the review closes.

Source filing ↗

Going concern Filing comparison

Silence Therapeutics plc disclosed substantial doubt about its ability to continue as a going concern

No going-concern disclosure → Substantial doubt about ability to continue as a going concern

As of December 31, 2025, the Group had cash and cash equivalents and short-term investments of $85.1 million. In accordance with Accounting Standards Codification ("ASC") 205, "Disclosure of Uncertainties about and Entity's Ability to Continue as a Going Concern, the Group has the responsibility to evaluate whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date that the financial statements are issued. The forecast for evaluating the going concern basis of the Group includes…
Evidence
Blank check
No
Comparable
Yes
Current state
substantial_doubt
Current state label
Substantial doubt about ability to continue as a going concern
Direction
escalated
Located in
going-concern note
Prior filed
2025-04-30
Prior form
10-K/A
Prior state
none
Prior state label
No going-concern disclosure
Source
ASC 205-40 going-concern note comparison
Why
Disclosure about the company's ability to continue as a going concern changed compared with its previous report.

Source filing ↗ Prior filing ↗